BioCentury | Oct 21, 2020
Finance

Oct. 20 Quick Takes: AbSci raises $65M; plus Aptinyx, Synspira and Aridis

Casdin leads $65M round for AbSciProtein manufacturing company AbSci LLC said it raised $65 million in a series E round led by Casdin Capital. First-time backers Redmile Group and ArrowMark Partners joined returning investor Phoenix...
BioCentury | Oct 17, 2020
Regulation

CHMP’s October recommendations

EMA’s CHMP has backed autologous cells therapies Tecartus, from Gilead, and Lebmeldy, from Orchard, in its October set of opinions. The agency recommended conditional marketing approval for Tecartus brexucabtagene autoleucel from the Kite Pharma Inc....
BioCentury | Oct 6, 2020
Product Development

Argentina study moves needle away from convalescent plasma for COVID-19

A randomized, placebo-controlled trial in Argentina has found that convalescent plasma is not effective in severe COVID-19 patients, casting more doubt on the efficacy data FDA used to back the...
BioCentury | Sep 18, 2020
Product Development

Sept. 17 Quick Takes: Another Tecfidera setback for Biogen; plus ChemoCentryx PDUFA date and Amytrx’s debut

Tecfidera patent ruling another setback for BiogenThe U.S. District Court for the District of Delaware concluded that another court’s prior ruling invalidating a patent for Tecfidera dimethyl fumarate from Biogen Inc. (NASDAQ:BIIB) does apply under...
BioCentury | Aug 31, 2020
Deals

Takeout premium shows Nestlé’s faith in Aimmune peanut product, despite launch slowed by COVID

Nestlé Health Science’s premium-priced takeout of peanut allergy company Aimmune is its biggest move yet in biotech, giving it full control of a marketed program in which the nutrition company had already invested heavily. The...
BioCentury | Aug 1, 2020
Tools & Techniques

Lurie winner and incoming Genentech R&D chief Aviv Regev looks to gene programs to untangle complex diseases

Single cell pioneer Aviv Regev thinks the gene networks revealed by the technology are on the verge of delivering new ways to attack disease biology. Her emphasis is on the idea that uncovering how genes...
BioCentury | Jul 29, 2020
Product Development

July 28 Quick Takes: Spectrum gains on NSCLC data; plus Nabriva, Farxiga, Chi-Med, Merck-Lumos, BeiGene, Aerie, jCyte and moreBy BioCentury Staff

Spectrum therapy hits Phase II endpoint Poziotinib met the prespecified primary endpoint in the ZENITH20 Phase II trial in previously treated non-small cell lung cancer (NSCLC) patients with HER2 exon 20 insertion mutations (Cohort 2),...
BioCentury | Jun 26, 2020
Finance

Poseida brings in $110M ahead of IPO as more biotechs line up for NASDAQ debuts

June has already seen 13 biopharmas raise more than a total of $4.7 billion from NASDAQ IPOs, and biotechs are continuing to line up for public market debuts (see “Biotech IPOs on NASDAQ Maintain Momentum”...
BioCentury | May 29, 2020
Finance

Taiho’s new modality search engine

With its parent company focused on small molecules for cancer, Taiho Ventures is using a recently upsized fund to find cutting edge modalities that take Taiho Pharmaceutical beyond its internal expertise. President Sakae Asanuma established...
BioCentury | May 27, 2020
Top Story

Arcus keeps its independence in deal that gives Gilead access to targets ripe for combinations

Gilead’s partnership with Arcus gives it access to a pipeline ripe for immuno-oncology combinations around closely watched targets, such as TIGIT. But the agreement doesn’t mirror Gilead’s last deal, in which partnering negotiations with Forty...
Items per page:
1 - 10 of 504